Dyspnea As a Prognostic Factor in Patients with Non-Small Cell Lung Cancer

Overview

Journal Yonsei Med J

Specialty General Medicine

Date 2016 Jul 13

PMID 27401635

Citations 20

Authors

Woo Ho Ban

Jong Min Lee

Jick Hwan Ha

Chang Dong Yeo

Hyeon Hui Kang

Chin Kook Rhee

Hwa Sik Moon

Sang Haak Lee

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate associations between dyspnea and clinical outcomes in patients with non-small cell lung cancer (NSCLC).

Materials And Methods: From 2001 to 2014, we retrospectively reviewed the prospective lung cancer database of St. Paul's Hospital at the Catholic University of Korea. We enrolled patients with NSCLC and evaluated symptoms of dyspnea using modified Medical Research Council (mMRC) scores. Also, we estimated pulmonary functions and analyzed survival data.

Results: In total, 457 NSCLC patients were enrolled, and 259 (56.7%) had dyspnea. Among those with dyspnea and whose mMRC scores were available (109 patients had no mMRC score), 85 (56.6%) patients had an mMRC score <2, while 65 (43.3%) had an mMRC score ≥2. Significant decreased pulmonary functions were observed in patients with dyspnea. In multivariate analysis, aging, poor performance status, advanced stage, low forced expiratory volume in 1 second (%), and an mMRC score ≥2 were found to be significant prognostic factors for patient survival.

Conclusion: Dyspnea could be a significant prognostic factor in patients with NSCLC.

Citing Articles

Evaluating the effect of immune checkpoint inhibitor treatment on chronic obstructive pulmonary disease in lung cancer patients.

Greib A, Zhao S, Ploch M, Henricks J, Easterling R, Moodabagil M Oncoimmunology. 2025; 14(1):2469375.

PMID: 39981683 PMC: 11849934. DOI: 10.1080/2162402X.2025.2469375.

Symptom burden and clusters during chemotherapy in patients with lung cancer.

Wang Y, Fang L, Zhou K, Xie Y, Yang S, Liu S World J Surg Oncol. 2024; 22(1):309.

PMID: 39578897 PMC: 11583389. DOI: 10.1186/s12957-024-03594-0.

Symptom clusters and symptom network analysis during immunotherapy in lung cancer patients.

Yang X, Bai J, Liu R, Wang X, Zhang G, Zhu X Support Care Cancer. 2024; 32(11):717.

PMID: 39382716 DOI: 10.1007/s00520-024-08918-0.

The effect of pulmonary rehabilitation on quality of life and functional capacity after chemotherapy in patients with small cell lung cancer.

Kocamaz D, Dinler E, Yamak D, Hatimogullari K, Bayramlar K, Yildirim M Support Care Cancer. 2024; 32(10):678.

PMID: 39305337 DOI: 10.1007/s00520-024-08880-x.

Associations Between Preoperative Shortness of Breath and Potassium Channels Gene Variations in Women With Breast Cancer.

Shin J, Hammer M, Paul S, Conley Y, Harris C, Oppegaard K Biol Res Nurs. 2024; 27(1):81-90.

PMID: 39137431 PMC: 11788816. DOI: 10.1177/10998004241268088.

References

Blanchon F, Grivaux M, Asselain B, Lebas F, Orlando J, Piquet J . 4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. Lancet Oncol. 2006; 7(10):829-36. DOI: 10.1016/S1470-2045(06)70868-3. View

Sarna L, Evangelista L, Tashkin D, Padilla G, Holmes C, Brecht M . Impact of respiratory symptoms and pulmonary function on quality of life of long-term survivors of non-small cell lung cancer. Chest. 2004; 125(2):439-45. DOI: 10.1378/chest.125.2.439. View

Thongprasert S, Duffield E, Saijo N, Wu Y, Yang J, Chu D . Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol. 2011; 6(11):1872-80. DOI: 10.1097/JTO.0b013e31822adaf7. View

Foroulis C, Lioulias A, Papakonstantinou C . Simple laboratory parameters which can determine the clinical state of patients after pneumonectomy for lung cancer. J Thorac Oncol. 2008; 4(1):55-61. DOI: 10.1097/JTO.0b013e3181914d6a. View

Vermaelen K, Brusselle G . Exposing a deadly alliance: novel insights into the biological links between COPD and lung cancer. Pulm Pharmacol Ther. 2013; 26(5):544-54. DOI: 10.1016/j.pupt.2013.05.003. View

Cella D, Bonomi A, Lloyd S, Tulsky D, Kaplan E, Bonomi P . Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 1995; 12(3):199-220. DOI: 10.1016/0169-5002(95)00450-f. View

Luengo-Fernandez R, Leal J, Gray A, Sullivan R . Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013; 14(12):1165-74. DOI: 10.1016/S1470-2045(13)70442-X. View

Charpidou A, Gkiozos I, Tsimpoukis S, Apostolaki D, Dilana K, Karapanagiotou E . Therapy-induced toxicity of the lungs: an overview. Anticancer Res. 2009; 29(2):631-9. View

Denehy L, Hornsby W, Herndon 2nd J, Thomas S, Ready N, Granger C . Prognostic validation of the body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index in inoperable non-small-cell lung cancer. J Thorac Oncol. 2014; 8(12):1545-50. DOI: 10.1097/JTO.0000000000000032. View

10.

Hashimoto N, Matsuzaki A, Okada Y, Imai N, Iwano S, Wakai K . Clinical impact of prevalence and severity of COPD on the decision-making process for therapeutic management of lung cancer patients. BMC Pulm Med. 2014; 14:14. PMC: 3922111. DOI: 10.1186/1471-2466-14-14. View

11.

Young R, Hopkins R, Christmas T, Black P, Metcalf P, Gamble G . COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J. 2009; 34(2):380-6. DOI: 10.1183/09031936.00144208. View

12.

Vestbo J, Hurd S, Agusti A, Jones P, Vogelmeier C, Anzueto A . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2012; 187(4):347-65. DOI: 10.1164/rccm.201204-0596PP. View

13.

Carlson L, Waller A, Groff S, Bultz B . Screening for distress, the sixth vital sign, in lung cancer patients: effects on pain, fatigue, and common problems--secondary outcomes of a randomized controlled trial. Psychooncology. 2012; 22(8):1880-8. DOI: 10.1002/pon.3223. View

14.

De Ruysscher D, Dehing C, Yu S, Wanders R, Ollers M, Dingemans A . Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer. Radiother Oncol. 2008; 91(3):353-9. DOI: 10.1016/j.radonc.2008.10.006. View

15.

Walters S, Maringe C, Coleman M, Peake M, Butler J, Young N . Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007. Thorax. 2013; 68(6):551-64. DOI: 10.1136/thoraxjnl-2012-202297. View

16.

Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

17.

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

18.

Feinstein M, Krebs P, Coups E, Park B, Steingart R, Burkhalter J . Current dyspnea among long-term survivors of early-stage non-small cell lung cancer. J Thorac Oncol. 2010; 5(8):1221-6. PMC: 4515574. DOI: 10.1097/JTO.0b013e3181df61c8. View

19.

Nishimura K, Izumi T, Tsukino M, Oga T . Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002; 121(5):1434-40. DOI: 10.1378/chest.121.5.1434. View

20.

Celli B, Cote C, Marin J, Casanova C, Montes de Oca M, Mendez R . The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350(10):1005-12. DOI: 10.1056/NEJMoa021322. View